Intravitreal Bevacizumab to Treat Acute Central Serous Chorioretinopathy: Short-Term Effect

Abstract

Intravitreal bevacizumab injection for acute central serous chorioretinopathy may result in prompt resolution of neurosensory detachment and reduction of angiographic leakage. These short-term results suggest that intravitreal bevacizumab injection may constitute a promising therapeutic option in acute central serous chorioretinopathy.